138 related articles for article (PubMed ID: 38277114)
21. Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study.
Cramon P; Winther KH; Watt T; Bonnema SJ; Bjorner JB; Ekholm O; Groenvold M; Hegedüs L; Feldt-Rasmussen U; Rasmussen ÅK
Thyroid; 2016 Aug; 26(8):1010-8. PubMed ID: 27370744
[TBL] [Abstract][Full Text] [Related]
22. Clinical and biochemical changes following 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs.
Koornstra JJ; Kerstens MN; Hoving J; Visscher KJ; Schade JH; Gort HB; Leemhuis MP
Neth J Med; 1999 Nov; 55(5):215-21. PubMed ID: 10593131
[TBL] [Abstract][Full Text] [Related]
23. Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: results of one-year follow-up.
Regalbuto C; Marturano I; Condorelli A; Latina A; Pezzino V
J Endocrinol Invest; 2009 Feb; 32(2):134-8. PubMed ID: 19411811
[TBL] [Abstract][Full Text] [Related]
24. [Status of 3 years of hyperthyroidism treatment with iodine 131].
Delgrange E; Weber E; Michel L; De Coster P; Buysschaert M; Donckier J
Acta Clin Belg; 1994; 49(5):200-7. PubMed ID: 7992563
[TBL] [Abstract][Full Text] [Related]
25. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis.
Wiersinga WM; Poppe KG; Effraimidis G
Lancet Diabetes Endocrinol; 2023 Apr; 11(4):282-298. PubMed ID: 36848916
[TBL] [Abstract][Full Text] [Related]
26. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
[TBL] [Abstract][Full Text] [Related]
27. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
28. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
29. Empiric radioiodine for hyperthyroidism: Outcomes, prescribing patterns, and its place in the modern era of theranostics.
Boehm E; Kao YH; Lai J; Wraight PR; Sivaratnam DA
Clin Endocrinol (Oxf); 2022 Jul; 97(1):124-129. PubMed ID: 35508893
[TBL] [Abstract][Full Text] [Related]
30. Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay.
Hovens GC; Heemstra KA; Buiting AM; Stokkel MP; Karperien M; Ballieux BE; Pereira AM; Romijn JA; Smit JW
Nucl Med Commun; 2007 Feb; 28(2):123-7. PubMed ID: 17198353
[TBL] [Abstract][Full Text] [Related]
31. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
[TBL] [Abstract][Full Text] [Related]
32. The feasibility of low-dose oral lithium therapy and its effect on thyroidal radioiodine uptake, retention, and hormonal parameters in various subcategories of hyperthyroid patients: a pilot study.
Chouhan A; Abhyankar A; Basu S
Nucl Med Commun; 2016 Jan; 37(1):74-8. PubMed ID: 26465804
[TBL] [Abstract][Full Text] [Related]
33. Glycemic status in hyperthyroid subjects.
Paul DT; Mollah FH; Alam MK; Fariduddin M; Azad K; Arslan MI
Mymensingh Med J; 2004 Jan; 13(1):71-5. PubMed ID: 14747791
[TBL] [Abstract][Full Text] [Related]
34. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism.
Tarantini B; Ciuoli C; Di Cairano G; Guarino E; Mazzucato P; Montanaro A; Burroni L; Vattimo AG; Pacini F
J Endocrinol Invest; 2006; 29(7):594-8. PubMed ID: 16957406
[TBL] [Abstract][Full Text] [Related]
36. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre?
Körber C; Schneider P; Körber-Hafner N; Hänscheid H; Reiners C
Eur J Nucl Med; 2001 Sep; 28(9):1360-4. PubMed ID: 11585295
[TBL] [Abstract][Full Text] [Related]
37. Pattern of presentation of Graves' disease and response to radioiodine therapy in South African men.
Onimode YA; Dairo DM; Ellmann A
Pan Afr Med J; 2018; 29():48. PubMed ID: 29875930
[TBL] [Abstract][Full Text] [Related]
38. [Therapeutic results of radioiodine therapy of hyperthyroid thyroid gland diseases].
Debrand-Passard A; Barzen G; Richter W; Wenzel KW; Felix R
Med Klin (Munich); 1994 Jun; 89(6):319-23. PubMed ID: 8072455
[TBL] [Abstract][Full Text] [Related]
39. Five-year follow-up of percutaneous ethanol injection for the treatment of hyperfunctioning thyroid nodules: a study of 117 patients.
Monzani F; Caraccio N; Goletti O; Lippolis PV; Casolaro A; Del Guerra P; Cavina E; Miccoli P
Clin Endocrinol (Oxf); 1997 Jan; 46(1):9-15. PubMed ID: 9059552
[TBL] [Abstract][Full Text] [Related]
40. Painless thyroiditis mimicking relapse of hyperthyroidism during or after potassium iodide or thionamide therapy for Graves' disease resulting in remission.
Okamura K; Sato K; Fujikawa M; Bandai S; Ikenoue H; Kitazono T
Endocr J; 2023 Feb; 70(2):207-222. PubMed ID: 36351595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
